5700-04-9

Basic information

• Product Name: 1,3-DIAZEPANE-2-THIONE
• Synonyms: 1,3-DIAZEPANE-2-THIONE;hexahydro-1,3-diazepin-2-thione;hexahydro-3-diazepin-2-thione;NNTETRAMETHYLENETHIOUREA
• CAS NO: 5700-04-9
• Molecular Formula: C₅H₁₀N₂S
• Molecular Weight: 130.21
• Mol File: 5700-04-9.mol
• Article Data: 18

Chemical Properties

• Melting Point: 178 °C
• Boiling Point: 194.4°C at 760 mmHg
• Flash Point: 71.4°C
• Appearance: /
• Density: 1.14g/cm³
• Vapor Pressure: 0.443mmHg at 25°C
• Refractive Index: 1.576
• CAS DataBase Reference: 1,3-DIAZEPANE-2-THIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-DIAZEPANE-2-THIONE(5700-04-9)
• EPA Substance Registry System: 1,3-DIAZEPANE-2-THIONE(5700-04-9)

Safety Data

• Hazardous Substances Data: 5700-04-9(Hazardous Substances Data)

Usage

Uses

1,3-Diazepane-2-thione (Diap) is used in the synthesis of new cadmium chloride complexes (e.g. Cd(Diap)2Cl2 ) which exhibit substantial antibacterial activities.

InChI:InChI=1/C5H10N2S/c8-5-6-3-1-2-4-7-5/h1-4H2,(H2,6,7,8)

Upstream product

• 51250-16-9 S-aminobutyl-N-dithiocarbamic acid 
• 137-26-8 Thiram 
• 110-60-1 1,4-diaminobutane 
• 97-74-5 bis(dimethylthiocarbamoyl)sulfide 
• 3358-42-7 4,5,6,7-tetrahydro-2-(methylthio)-1H-1,3-diazepine hydriodide 
• 7440-44-0 pyrographite 
• 110-52-1 1,4-dibromo-butane 
• 17356-08-0 thiourea 
• 56-23-5 tetrachloromethane 
• 75-15-0 carbon disulfide 
• 19055-93-7 1,3-diazepan-2-one 

Downstream Products

• 19055-93-7 1,3-diazepan-2-one 
• 730911-25-8 2,3,5,6,7,8-hexahydro-thiazolo[3,2-a][1,3]diazepine 
• 25565-93-9 3-p-Biphenylyl-5,6,7,8-tetrahydro-thiazolo<3,2-a>-<1,3>diazepin 
• 68291-00-9 3-(4-chloro-phenyl)-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]diazepine 
• 68290-99-3 3-(3-nitro-phenyl)-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]diazepine 
• 92897-50-2 2-[1-(4-Methoxy-phenyl)-meth-(Z)-ylidene]-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]diazepin-3-one 
• 25565-82-6 3-(4-aminobutyl)-1,3-thiazolidine-2,4-dione hydrochloride 
• 25565-84-8 2-bromo-2-(bromo-phenyl-methyl)-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]diazepin-3-one 
• 25565-80-4 2-benzylidene-4,5,6,7-tetrahydro-4H-diazepino<2,1-b>thiazol-3(2H)-one 
• 25565-83-7 3-(4-amino-butyl)-5-benzylidene-thiazolidine-2,4-dione; hydrochloride 
• 16597-36-7 1,3-dimethyl-1,3-diaza-2-cycloheptanethione 
• 25565-81-5 2-(4-dimethylamino-benzylidene)-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]diazepin-3-one 
• 25565-85-9 2-bromo-2-[bromo-(4-dimethylamino-phenyl)-methyl]-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]diazepin-3-one 

Relevant articles and documents

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

The present disclosure provides modified oligonucleotides and compositions and methods thereof. In some embodiments, provided technologies comprise modified sugars and/or modified internucleotidic linkages. In some embodiments, the present disclosure provides technologies for preparing modified oligonucleotides. In some embodiments, the present disclosure provides chirally controlled oligonucleotide compositions and methods for their preparation and uses.

Bis-(triethylphosphine)platinum(II) complexes with thiones as anti cancer agents

Platinum(II) complexes having mixed ligands as anticancer agents. The central platinum atom is coordinated by two phosphine ligands and two heterocyclic thione ligands. Each heterocyclic thione ligand has a five-, six- or seven-membered heterocyclic ring with two nitrogen atoms at positions 1 and 3 of the ring and a thiocarbonyl group at position 2. Pharmaceutical compositions incorporated the platinum(II) complexes, methods of synthesizing the complexes and methods of treating cancers with the complexes or pharmaceutical compositions thereof are also described.

Platinum(II) complexes with thione ligands and methods thereof

Platinum(II) complexes having thione-based heterocyclic ligands as anticancer agents. The central platinum atom is coordinated by four of the ligands, each having a five-, six- or seven-membered heterocyclic ring with two nitrogen atoms at positions 1 and 3 of the ring and a thiocarbonyl group at position 2. Pharmaceutical compositions incorporated the platinum(II) complexes, methods of synthesizing the complexes and methods of treating cancers with the complexes or pharmaceutical compositions thereof are also described.